期刊文献+

绝经后骨质疏松症的激素替代疗法益处与风险评估 被引量:8

Benefits and risk assessment of hormone replacement therapy for postmenopausal women with osteoporosis
暂未订购
导出
摘要 目的:对激素替代疗法(hormonereplacementtherapy,HRT)在防治绝经后骨质疏松症作用机制,以及HRT与骨密度、心血管病、乳腺癌等方面的关系作一综述,为绝经后骨质疏松症患者应用激素替代疗法治疗提供理论依据。资料来源:应用计算机检索Medline1997-01/2004-06期间的相关文章,检索词“Hormonereplacementtherapy,Postmenopausalwomen,osteo-porosis”,并限定文章语言种类为English。同时手工检索/或计算机检索《中国临床康复》杂志1990-01/2001-04期间的相关文章,限定文章语言种类为中文,检索词“激素替代疗法;绝经;骨质疏松”。资料选择:对资料进行初审,选取试验包括激素替代治疗对绝经后妇女骨密度、心血管病、乳腺癌等方面的文献,筛除明显不随机的临床试验的研究,对剩余的文献查找全文进一步判断是否为随机对照临床试验。纳入标准为①随机对照临床试验(RCT),无论是单盲,双盲或非盲法。②试验包含对照组和治疗组。资料提炼:共收集到45篇关于HRT的随机和未随机试验,33个试验符合纳入标准。排除的12篇试验中,7篇系重复的同一研究,5篇为Meta分析研究。资料综合:33个试验包括1176336例绝经后妇女,对应用HRT防治绝经后骨质疏松症者分别对骨密度、心血管病和乳腺癌等方面作了评估。结论:HRT要严格挑选适应证。
出处 《中国临床康复》 CSCD 2004年第36期8272-8274,共3页 Chinese Journal of Clinical Rehabilitation
  • 相关文献

参考文献30

  • 1Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science 2000;289(5484): 1508 - 14
  • 2Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998; 95 (7): 3597 - 602
  • 3Delmas PD. Hormone replacement therapy in the prevention and treatment of osteoporosis. Osteoporosis Int 1997;7(Suppl 1): S3-7
  • 4Hosking D, Chrilvers CE, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl Med 1998;338 (8): 485 - 92
  • 5Tiras MB, Noyan V, Yildiz A, et al. Comparison of different modalities for postmenopausal patients with osteopenia: Hormone replacement therapy, calcitonin and clodronate. Climacteric 2000;3(2): 92-101
  • 6Bjarnason NH, Alexanderser P, Christiansen C. Number of years since menopause: Spontaneous bone loss is dependent but response to hormone replacement therapy is independent. Bone 2002; 30 (4): 637 - 42
  • 7Wu F, Ames R, Clearwater J, et al. Prospective 10-year study of the determinants of bone density and bone loss in normal postmenopausal women including the effect of hormone replacement therapy. Clin Endocrinol(OxF) 2002; 56(6):703 - 11
  • 8Michaelsson K, Baron JA, Farahmand BY, et al. Hormone replacement therapy and risk of hip fracture: Population based case-control study. Br Med 1998; 316(7148): 1858-63
  • 9Bemben DA, Landon DB. Relationship between estrogen use and musculoskeletal function in postmenopausal women. Maturitas 2002 ;42 (2): 119 -27
  • 10Greenspan SL, Emkey RD, Bone HG, et al. Significant differential effects of alendronate, estrogen, or combination therapy on the ratio of bone loss after discontinuation of treatment of postmenopausal osteoporosis. Ann Intern Med 2002;137(11): 875 -83

同被引文献56

引证文献8

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部